Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below 200 Day Moving Average of $2.97

Minerva Neurosciences, Inc. (NASDAQ:NERV) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.97 and traded as low as $2.59. Minerva Neurosciences shares last traded at $2.61, with a volume of 3,790 shares.

Analyst Ratings Changes

NERV has been the topic of several recent analyst reports. StockNews.com initiated coverage on Minerva Neurosciences in a research note on Saturday. They issued a “sell” rating on the stock. HC Wainwright cut their target price on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th.

Minerva Neurosciences Stock Up 0.8 %

The company’s fifty day moving average price is $2.95 and its 200-day moving average price is $2.92. The stock has a market capitalization of $18.25 million, a PE ratio of -0.58 and a beta of 0.14.

Minerva Neurosciences (NASDAQ:NERV) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Equities research analysts anticipate that Minerva Neurosciences, Inc. will post -2.26 earnings per share for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.